TEL AVIV, Israel, May 8, 2017 /PRNewswire/ -- Galmed
Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a
clinical-stage biopharmaceutical company focused on the development
of a once-daily, oral therapy for the treatment of nonalcoholic
steatohepatitis, or NASH, and other liver diseases, announced today
that it will host a conference call and webcast on Monday, May 15th, 2017, to discuss
results for the period ended March 31, 2017 and to
provide an update on current developments with respect to its
clinical programs for Aramchol™.
Conference Call &
Webcast:
Monday, May
15th, 2017, 8:30 am
Eastern Time / 5:30 am Pacific
Time
Participant Dial-In Numbers:
Toll-Free:
|
+1-888-587-0613
|
|
Toll/International:
|
+1-719-457-2083
|
|
Conference
ID:
|
6659068
|
|
Webcast:
|
http://galmedpharma.investorroom.com/events
|
|
Replay, available until May 29,
2017
Replay Dial-In Numbers:
Toll-Free:
|
+1-844-512-2921
|
|
Toll/International:
|
+1-412-317-6671
|
|
Passcode:
|
6659068
|
|
About AramcholTM and Non-alcoholic
Steatohepatitis (NASH)
AramcholTM (arachidyl
amido cholanoic acid) is a novel fatty acid bile acid conjugate,
inducing beneficial modulation of intra-hepatic lipid metabolism.
AramcholTM's ability to modulate hepatic lipid
metabolism was discovered and validated in animal models,
demonstrating down regulation of the three key pathologies of NASH;
steatosis, inflammation and fibrosis. The effect of
AramcholTM on fibrosis is mediated by down regulation of
steatosis and directly on human collagen producing cells.
AramcholTM has been granted by the FDA Fast Track
designation status for the treatment of NASH.
NASH is an emerging world crisis impacting 3% to 5% of the U.S.
population and 2% to 4% globally. It is the fastest growing cause
of liver cancer and liver transplant in the U.S. due to the rise in
obesity. NASH is the progressive form of non alcoholic fatty liver
disease that can lead to cardiovascular disease, cirrhosis and
liver-related mortality .
About Galmed Pharmaceuticals Ltd.:
Galmed is a
clinical-stage biopharmaceutical company focused on the development
of AramcholTM, a first in class, novel, once-daily, oral
therapy for the treatment of NASH for variable populations, as well
as other liver associated disorders. Galmed is currently conducting
the ARREST Study, a multicenter, randomized, double blind,
placebo-controlled Phase IIb clinical study designed to evaluate
the efficacy and safety of AramcholTM in subjects with
NASH, who are overweight or obese, and who are pre-diabetic or
type-II-diabetic. Galmed also sponsors the ARRIVE Study, a
proof-of-concept Phase IIa clinical trial designed to evaluate the
safety and efficacy of Aramachol in
up to 50 patients with HIV-associated NAFLD and lipodystrophy. The
ARRIVE Study is an investigator-initiated trial, conducted at the
University of California San Diego by
Professor Rohit Loomba. More
information about the ARREST Study and the ARRIVE Study may be
found on ClinicalTrials.gov identifiers: NCT02279524 and
NCT02684591, respectively.
Forward-Looking Statements:
This press release may
include forward-looking statements. Forward-looking statements may
include, but are not limited to, statements relating to Galmed's
objectives, plans and strategies, as well as statements, other than
historical facts, that address activities, events or developments
that Galmed intends, expects, projects, believes or anticipates
will or may occur in the future. These statements are often
characterized by terminology such as "believes," "hopes," "may,"
"anticipates," "should," "intends," "plans," "will," "expects,"
"estimates," "projects," "positioned," "strategy" and similar
expressions and are based on assumptions and assessments made in
light of management's experience and perception of historical
trends, current conditions, expected future developments and other
factors believed to be appropriate. Forward-looking statements are
not guarantees of future performance and are subject to risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied in such statements. Applicable
risks and uncertainties include risks and uncertainties associated
with the initiation, timing, progress and results of the Company's
research, preclinical studies and clinical trials as well as risks
and uncertainties identified under the heading "Risk Factors"
included in Galmed's most recent Annual Report on Form 20-F filed
with the Securities and Exchange Commission, or the SEC, on
March 23, 2017, and in other filings
that Galmed has made and may make with the SEC in the future. The
forward-looking statements contained in this press release are made
as of the date of this press release and reflect Galmed's current
views with respect to future events, and Galmed does not undertake
and specifically disclaims any obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/galmed-pharmaceuticals-first-quarter-2017-conference-call-and-webcast-scheduled-for-monday-may-15th-2017-300452774.html
SOURCE Galmed Pharmaceuticals Ltd.